X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DIVIS LABORATORIES ASTRAZENECA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 158.2 38.5 411.2% View Chart
P/BV x 24.6 6.2 393.8% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DIVIS LABORATORIES
Mar-18
ASTRAZENECA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2851,142 112.5%   
Low Rs634533 118.9%   
Sales per share (Unadj.) Rs189.6146.6 129.3%  
Earnings per share (Unadj.) Rs-0.233.0 -0.6%  
Cash flow per share (Unadj.) Rs3.838.4 10.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs68.6222.8 30.8%  
Shares outstanding (eoy) m25.00265.47 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.15.7 88.6%   
Avg P/E ratio x-4,712.725.3 -18,590.8%  
P/CF ratio (eoy) x249.621.8 1,144.5%  
Price / Book Value ratio x14.03.8 372.0%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m23,988222,318 10.8%   
No. of employees `0001.610.8 14.5%   
Total wages/salary Rs m1,6054,561 35.2%   
Avg. sales/employee Rs Th3,040.23,616.0 84.1%   
Avg. wages/employee Rs Th1,029.2423.8 242.9%   
Avg. net profit/employee Rs Th-3.3814.9 -0.4%   
INCOME DATA
Net Sales Rs m4,74038,915 12.2%  
Other income Rs m921,134 8.1%   
Total revenues Rs m4,83240,049 12.1%   
Gross profit Rs m-13012,617 -1.0%  
Depreciation Rs m1011,425 7.1%   
Interest Rs m013 0.0%   
Profit before tax Rs m-13912,313 -1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m53,543 0.1%   
Profit after tax Rs m-58,770 -0.1%  
Gross profit margin %-2.732.4 -8.4%  
Effective tax rate %-3.728.8 -12.7%   
Net profit margin %-0.122.5 -0.5%  
BALANCE SHEET DATA
Current assets Rs m2,72645,351 6.0%   
Current liabilities Rs m2,4356,507 37.4%   
Net working cap to sales %6.199.8 6.2%  
Current ratio x1.17.0 16.1%  
Inventory Days Days74127 58.2%  
Debtors Days Days4195 42.8%  
Net fixed assets Rs m1,03521,160 4.9%   
Share capital Rs m50531 9.4%   
"Free" reserves Rs m94258,625 1.6%   
Net worth Rs m1,71659,156 2.9%   
Long term debt Rs m00-   
Total assets Rs m4,15667,832 6.1%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 198.8%   
Return on assets %-0.112.9 -0.9%  
Return on equity %-0.314.8 -2.0%  
Return on capital %020.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.521.8 29.6%   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m3068,485 3.6%   
Fx inflow Rs m37532,359 1.2%   
Fx outflow Rs m4709,042 5.2%   
Net fx Rs m-9623,317 -0.4%   
CASH FLOW
From Operations Rs m-87,759 -0.1%  
From Investments Rs m-146-4,783 3.0%  
From Financial Activity Rs m862-3,142 -27.4%  
Net Cashflow Rs m709-166 -426.8%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 15.7 19.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   12,856 31,796 40.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 26, 2018 02:37 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS